Nanodrug delivery in reversing multidrug resistance in cancer cells

Frontiers in Pharmacology

Volumn 5 JUL, Issue , 2014, Pages

  Kapse Mistry, Sonali ^a   Govender, Thirumala ^b   Srivastava, Rohit ^c   Yergeri, Mayur ^a  

^a SVKM S DR BHANUBEN NANAVATI COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Drug efflux pumps; Multidrug resistance; Nanodrug delivery systems; Theragnostic; Tumor microenvironment

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER INHIBITOR; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CELL DNA; CERAMIDE; CYTOTOXIC AGENT; DENDRIMER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INORGANIC COMPOUND; INORGANIC NANOPARTICLE; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; METAL NANOPARTICLE; MICRORNA; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN ANTIBODY; NANOCARRIER; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYMER; PROTEIN BCL 2; QUANTUM DOT; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BCL 2 GENE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER STEM CELL; DNA DAMAGE; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION; HIF1ALPHA GENE; HUMAN; HYPERTHERMIC THERAPY; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TUMOR MICROENVIRONMENT; ULTRASOUND THERAPY;

EID: 84904730938     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00159     Document Type: Review

References (226)

1. Ahmed, N., Fessi, H., and Elaissari, A. (2012). Theranostic applications of nanoparticles in cancer. Drug Discov. Today 17, 928-934. doi: 10.1016/j.drudis.2012.03.010
2. Al-Bataineh, M., van der Merwe, D., Schultz, B., and Gehring, R. (2010). Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells. Biopharm. Drug Dispos. 31, 506-515. doi: 10.1002/bdd.731
3. Alberto, G., Hilary, S., Aviva, T., Samuel, Z., Wang, S., Lee, R., et al. (2004). Tumor cell targeting of liposome entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56, 1177-1192. doi: 10.1016/j.addr.2004.01.011
4. Antony, A. (1996). Folate receptors. Annu. Rev. Nutr. 16, 501-521.
5. Ayers, D., and Nasti, A. (2012). Utilisation of nanoparticle technology in cancer chemoresistance. J. Drug Deliv. 2012:265691. doi: 10.1155/2012/265691
6. Banerjee, R., Tyagi, P., Li, S., and Huang, L. (2004). Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer 112, 693-700. doi: 10.1002/ijc.20452
7. Barth, M., Brian, C., Cabot, M., and Kester, M. (2011). Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med. Chem. 11, 911-919. doi: 10.2174/187152011797655177
8. Baud, V., and Karin, M. (2009). Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33-40. doi: 10.1038/nrd2781
9. Beh, C., Seow, W., Wang, Y., Zhang, Y., Ong, Z., Ee, P., et al. (2009). Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10, 41-48. doi: 10.1021/bm801109g
10. Bernardi, A., Braganhol, E., Jäger, E., Figueiró, F., Edelweiss, M., Pohlmann, A., et al. (2009). Indomethacin loaded nanocapsules treatment reduces in-vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53-63. doi: 10.1016/j.canlet.2009.02.018
11. Bielawski, K., Bielawska, A., Muszynska, A., Poplawska, B., and Czarnomysy, R. (2011). Cytotoxic activity of G3 PAMAM-NH2 dendrimer-chlorambucil conjugate in human breast cancer cells. Environ. Toxicol. Pharmacol. 32, 364-372. doi: 10.1016/j.etap.2011.08.002
12. Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., et al. (2007). Polymeric nanoparticle-encapsulated Curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5:3. doi: 10.1186/1477-3155-5-3
13. Boddapati, S., D'Souza, G., Erdogan, S., Torchilin, V., and Weissig, V. (2008). Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8, 2559-2563. doi: 10.1021/nl801908y
14. Brown, S., Nativo, P., Smith, J., Stirling, D., Edwards, P., Venugopal, B., et al. (2010). Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc. 132, 4678-4684. doi: 10.1021/ja908117a
15. Broxterman, H., Lankelma, J., and Hoekman, K. (2003). Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 6, 111-127. doi: 10.1016/S1368-7646(03)00026-8
16. Cambón, A., Rey-Rico, A., Mistry, D., Brea, J., Loza, M., Attwood, D., et al. (2013). Doxorubicin-loaded micelles of reverse poly(butylene oxide)-poly(ethylene oxide)-poly(butylene oxide) block copolymers as efficient "active" chemotherapeutic agents. Int. J. Pharm. 445, 47-57. doi: 10.1016/j.ijpharm.2013.01.056
17. Chanda, N., Kattumuri, V., Shukla, R., Zambre, A., Katti, K., Upendran, A., et al. (2010). Bombesin functionalized gold nanoparticles show in-vitro and in-vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U.S.A. 107, 8760-8765. doi: 10.1073/pnas.1002143107
18. Chanda, N., Shukla, R., Katti, K., and Kannan, R. (2009). Gastrin releasing protein receptor specific gold nanorods: breast and prostate tumor avid nanovectors for molecular imaging. Nano Lett. 9, 1798-1805. doi: 10.1021/nl8037147
19. Chapman, J., Gouazé-Andersson, V., Messner, M., Flowers, M., Karimi, R., Kester, M., et al. (2010). Metabolism of short-chain ceramide by human cancer cells-Implications for therapeutic approaches. Biochem. Pharmacol. 80, 308-315. doi: 10.1016/j.bcp.2010.04.001
20. Chavanpatil, M., Khdair, A., Gerard, B., Bachmeier, C., Miller, D., Shekhar, M., et al. (2007). Surfactant-polymer nanoparticles overcome P-glycoprotein- mediated drug efflux. Mol. Pharm. 4, 730-738. doi: 10.1021/mp070024d
21. Chavanpatil, M., Patil, Y., and Panyam, J. (2006). Susceptibility of nanoparticle-encapsulated Paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm. 320, 150-156. doi: 10.1016/j.ijpharm.2006.03.045
22. Chen, A., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., et al. (2009a). Co-delivery of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant. Small 5, 2673-2677. doi: 10.1002/smll.200900621
23. Chen, B., Lai, B., Cheng, J., Xia, G., Gao, F., Xu, W., et al. (2009b). Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in-vivo. Int. J. Nanomedicine 4, 201-208. doi: 10.2147/IJN.S7287
24. Chen, B., Sun, Q., Wang, X., Gao, F., Dai, Y., Yin, Y., et al. (2008). Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with Adriamycin and tetrandrine in K562/A02 leukemic cells. Int. J. Nanomedicine 3, 277-286.
25. Chen, Y., Bathula, S., Li, J., and Huang, L. (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 285, 22639-22650. doi: 10.1074/jbc.M110.125906
26. Chen, Y., Yin, Q., Ji, X., Zhang, S., Chen, H., Zheng, Y., et al. (2012). Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells. Biomaterials 33, 7126-7137. doi: 10.1016/j.biomaterials.2012.06.059
27. Chen, Y., Zhang, W., Gu, J., Ren, Q., Fan, Z., Zhong, W., et al. (2013). Enhanced antitumor efficacy by methotrexate conjugated pluronic mixed micelles against KBv multidrug resistant cancer. Int. J. Pharm. 452, 421-433. doi: 10.1016/j.ijpharm.2013.05.015
28. Chichel, A., Skowronek, J., Kubaszewska, M., and Kanikowski, M. (2007). Hyperthermia - description of a method and a review of clinical applications. Rep. Pract. Oncol. Radiother. 12, 267-275. doi: 10.1016/S1507-1367(10)60065-X
29. Chiu, S., Liu, S., Perrotti, D., Marcucci, G., and Lee, R. (2006). Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J. Control. Release 112, 199-207. doi: 10.1016/j.jconrel.2006.02.011
30. Cho, H., Yoon, H., Koo, H., Ko, S., Shim, J., Lee, J., et al. (2011). Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 32, 7181-7190. doi: 10.1016/j.biomaterials.2011.06.028
31. Cho, H., Yoon, I., Yoon, H., Koo, H., Jin, Y., Ko, S., et al. (2012). Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 33, 1190-1200. doi: 10.1016/j.biomaterials.2011.10.064
32. Cho, Y., Yoon, T., Jang, E., Hong, K., Lee, S., Kim, O., et al. (2010). Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in-vivo colon cancer targeting and imaging. Cancer Lett. 299, 63-71. doi: 10.1016/j.canlet.2010.08.004
33. Cirstoiu-Hapca, A., Buchegger, F., Bossy, L., Kosinski, M., Gurny, R., and Delie, F. (2009). Nanomedicines for active targeting: physicochemical characterization of Paclitaxel loaded antiHER2 immunonanoparticles and in vitro functional studies on target cells. Eur. J. Pharm. Sci. 38, 230-237. doi: 10.1016/j.ejps.2009.07.006
34. Conte, C., Ungaro, F., Maglio, G., Tirino, P., Siracusano, G., Sciortino, M., et al. (2013). Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn (II)-phthalocyanine inspired by combination therapy for cancer. J. Control. Release 167, 40-52. doi: 10.1016/j.jconrel.2012.12.026
35. Couvreur, P., and Vauthier, C. (1991). Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J. Control. Release 17, 187-198.
36. Dantzig, A., Alwis, D., and Burgess, M. (2003). Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55, 133-150. doi: 10.1016/S0169-409X(02)00175-8
37. Das, M., and Sahoo, S. (2012). Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS ONE 7:32920. doi: 10.1371/journal.pone.0032920
38. Davis, M., Zuckerman, J., and Choi, C. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070. doi: 10.1038/nature08956
39. Devalapally, H., Duan, Z., Seiden, M., and Amiji, M. (2007). Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer. 121, 1830-1838. doi: 10.1002/ijc.22886
40. Devalapally, H., Duan, Z., Seiden, M., and Amiji, M. (2008). Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 14, 3193. doi: 10.1158/1078-0432.CCR-07-4973
41. Dong, X., and Mumper, R. (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.) 5, 597-615. doi: 10.2217/nnm.10.35
42. Emami, J., Rezazadeh, M., Varshosaz, J., Tabbakhian, M., and Aslani, A. (2012). Formulation of LDL targeted nanostructured lipid carriers loaded with Paclitaxel: a detailed study of preparation, freeze drying condition and in-vitro cytotoxicity. J. Nanomater. 2012:358782. doi: 10.1155/2012/358782
43. Fan, L., Li, F., Zhang, H., Wang, Y., Cheng, C., Li, X., et al. (2010). Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31, 5634-5642. doi: 10.1016/j.biomaterials.2010.03.066
44. Fang, C., Kievit, F., Veiseh, O., Stephen, Z., Wang, T., Lee, D., et al. (2012). Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J. Control. Release 162, 233-241. doi: 10.1016/j.jconrel.2012.06.028
45. Fardel, O., Lecureur, V., and Guillouzo, A. (1996). The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27, 1283-1291.
46. Fox, E., and Bates, S. (2007). Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 7, 447-459. doi: 10.1586/14737140.7.4.447
47. Fukumura, D., and Jain, R. (2007). Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74, 72-84. doi: 10.1016/j.mvr.2007.05.003
48. Ganta, S., and Amiji, M. (2009). Co-administration of Paclitaxel and Curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6, 928-939. doi: 10.1021/mp800240j
49. Gao, Y., Chen, L., Zhang, Z., Chen, Y., and Li, Y. (2011). Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 32, 1738-1747. doi: 10.1016/j.biomaterials.2010.11.001
50. Gao, Z., Fain, H., and Rapoport, N. (2005). Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 102, 203-222. doi: 10.1016/j.jconrel.2004.09.021
51. Gao, Z., Zhang, L., and Sun, Y. (2012). Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 162, 45-55. doi: 10.1016/j.jconrel.2012.05.051
52. Gary-Bobo, M., Hocine, O., Brevet, D., Maynadier, M., Raehm, L., Richeter, S., et al. (2012). Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 423, 509-515. doi: 10.1016/j.ijpharm.2011.11.045
53. Geszke-Moritz, M., and Moritz, M. (2013). Quantum dots as versatile probes in medical sciences: synthesis, modification and properties. Mat. Sci. Eng. C 33, 1008-1021. doi: 10.1016/j.msec.2013.01.003
54. Gokhale, P., Radhakrishnan, B., Husain, S., Abernethy, D., Sacher, R., Dritschilo, A., et al. (1996). An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br. J. Cancer 74, 43-48
55. Gong, J., Chen, M., Zheng, Y., Wang, S., and Wang, Y. (2012). Polymeric micelles drug delivery system in oncology. J. Control. Release 159, 312-323. doi: 10.1016/j.jconrel.2011.12.012
56. Gu, Y., Cheng, J., Man, C., Wong, W., and Cheng, S. (2012). Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 8, 204-211. doi: 10.1016/j.nano.2011.06.005
57. Han, M., Diao, Y., Jiang, H., Ying, X., Chen, D., Liang, W., et al. (2011). Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int. J. Pharm. 420, 404-411. doi: 10.1016/j.ijpharm.2011.09.009
58. Hannun, Y., and Obeid, L. (1995). Ceramide: an intracellular signal for apoptosis. Trends Biochem. Sci. 20, 73-77. doi: 10.1016/S0968-0004(00)88961-6
59. Harris, A. (2002). Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 38-47. doi: 10.1038/nrc704
60. He, Q., Gao, Y., Zhang, L., Zhang, Z., Gao, F., Ji, X., et al. (2011). A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 32, 7711-7720. doi: 10.1016/j.biomaterials.2011.06.066
61. Howard, B., Gao, Z., and Lee, S. (2006). Ultrasound-enhanced chemotherapy of drug-resistant breast cancer tumors by micellar-encapsulated Paclitaxel. Am. J. Drug Deliv. 4, 97-104. doi: 10.2165/00137696-200604020-00005
62. Hun, X., Zhang, Z., and Tiao, L. (2008). Anti-Her-2 monoclonal antibody conjugated polymer fluorescent nanoparticles probe for ovarian cancer imaging. Anal. Chim. Acta 625, 201-206. doi: 10.1016/j.aca.2008.07.038
63. Indran, I., Tufo, G., Pervaiz, S., and Brenner, C. (2011). Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 1807, 735-745. doi: 10.1016/j.bbabio.2011.03.010
64. Jagani, H., Josyula, V., and Palanimuthu, V. (2013). Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating. Eur. J. Pharm. Sci. 48, 611-618. doi: 10.1016/j.ejps.2012.12.017
65. Javid, A., Ahmadian, S., Saboury, A., and Rezaei-Zarchi, S. (2011). Anticancer effect of doxorubicin loaded heparin based super-paramagnetic iron oxide nanoparticles against the human ovarian cancer cells. World Acad. Sci. Eng. Tech. 50.
66. Jia, L., Shen, J., Li, Z., Zhang, D., Zhang, Q., Liu, G., et al. (2013). In-vitro and in-vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. Inter. J. Pharm. 445, 12-19.
67. Jiang, Y., DiVittore, N., Kaiser, J., Shanmugavelandy, S., Fritz, J., Heakal, Y., et al. (2011). Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Landes Biosci. 12, 574-585. doi: 10.4161/cbt.12.7.15971
68. Jiang, Z., Chen, B., Wu, Q., Xia, G., Zhang, Y., Gao, F., et al. (2009). Reversal effect of Fe3O4-magnetic nanoparticles on multi-drug resistance of ovarian carcinoma cells and its correlation with apoptosis-associated genes. Chin. J. Cancer 28, 1158-1162. doi: 10.5732/cjc.009.10090
69. Kang, K., Chun, M.-K., Kim, O., Subedi, R. K., Ahn, S. G., Yoon, J. H., et al. (2010). Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed. Nanotech. Bio. Med. 6, 210-213. doi: 10.1016/j.nano.2009.12.006
70. Kedar, U., Phutane, P., Shidhaye, S., and Kadam, V. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6, 714-729. doi: 10.1016/j.nano.2010.05.005
71. Kelkar, S., and Reineke, T. (2011). Theranostics: combining imaging and therapy. Bioconjug. Chem. 22, 1879-1903. doi: 10.1021/bc200151q
72. Kesharwani, P., Tekade, R., Gajbhiye, V., Jain, K., and Jain, M. (2011). Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed. Nanotech. Bio. Med. 7, 295-304. doi: 10.1016/j.nano.2010.10.010
73. Khandare, J., Jayant, S., Singh, A., Chandna, P., Wang, Y., Vorsa, N., et al. (2006). Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconj. Chem. 17, 1464-1472. doi: 10.1021/bc060240p
74. Khdair, A., Handa, H., Mao, G., and Panyam, J. (2009). Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur. J. Pharm. Biopharm. 71, 214-222. doi: 10.1016/j.ejpb.2008.08.017
75. Kievit, F., Wang, F., Fang, C., Mok, H., Wang, K., Silber, J., et al. (2011). Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release 152, 76-83. doi: 10.1016/j.jconrel.2011.01.024
76. Kim, E., Jung, Y., Choi, H., Yang, J., Suh, J., Huh, Y., et al. (2010a). Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31, 4592-4599. doi: 10.1016/j.biomaterials.2010.02.030
77. Kim, J., Choi, W., Kim, M., and Tae, G. (2013). Tumor-targeting nanogel that can function independently for both photodynamic and photothermal therapy and its synergy from the procedure of PDT followed by PTT. J. Control. Release 171, 113-121. doi: 10.1016/j.jconrel.2013.07.006
78. Kim, K., Kim, J., Park, H., Kim, Y., Park, K., Nam, H., et al. (2010b). Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 146, 219-227. doi: 10.1016/j.jconrel.2010.04.004
79. Kirui, D., Khalidov, I., Wang, Y., and Batt, C. (2013). Targeted near-IR hybrid magnetic nanoparticles for in-vivo cancer therapy and imaging. Nanomed. Nanotech. Bio. Med. 9, 702-711. doi: 10.1016/j.nano.2012.11.009
80. Kos, J., Obermajer, N., Doljak, B., Kocbek, P., and Kristl, J. (2009). Inactivation of harmful tumor associated proteolysis by nanoparticulate system. Int. J. Pharm. 381, 106-112. doi: 10.1016/j.ijpharm.2009.04.037
81. Koshkaryev, A., Piroyan, A., and Torchilin, V. (2012). Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Bio. Ther. 13, 50-60. doi: 10.4161/cbt.13.1.18871
82. Kumar, A., and Liang, X. (2011). Gold nanoparticles: promising nanomaterials for the diagnosis of cancer and HIV/AIDS. J. Nanomater. 2011:202187. doi: 10.1155/2011/202187
83. Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., et al. (2012). Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 33, 1180-1189. doi: 10.1016/j.biomaterials.2011.10.058
84. Kumar, A., Xu, Z., and Xing-Jie, L. (2013). Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotech. Adv. 31, 593-606. doi: 10.1016/j.biotechadv.2012.10.002
85. Kumar, C., and Faruq, M. (2011). Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv. Drug Deliv. Rev. 63, 789-808. doi: 10.1016/j.addr.2011.03.008
86. Kuo, W., Ku, Y., Sei, H., Cheng, F., and Yeh, C. (2009). Paclitaxel-loaded stabilizer-free poly(D,L-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anti-cancer drug resistance and cancer cellular imaging. J. Chin. Chem. Soc. 56, 923-934. doi: 10.1002/jccs.200900136
87. Lage, H. (2009). Therapeutic potential of RNA interference in drug-resistant cancers. Future Oncol. 5, 169-185. doi: 10.2217/14796694.5.2.169
88. Lee, D., Lockey, R., and Mohapatra, S. (2006). Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans. J. Nanosci. Nanotechnol. 6, 2860-2866. doi: 10.1166/jnn.2006.465
89. Lee, E., Na, K., and Bae, Y. (2005). Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103, 405-418. doi: 10.1016/j.jconrel.2004.12.018
90. Lee, H., Kim, S., Choi, B., Park, M., Lee, J., Jeong, S., et al. (2011). Hyperthermia improves therapeutic efficacy of doxorubicin carried by mesoporous silica nanocontainers in human lung cancer cells. Int. J. Hyperthermia 27, 698-707. doi: 10.3109/02656736.2011.608217
91. Lee, R., and Low, P. (1995). Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in-vitro. Biochim. Biophys. Acta Biomembranes 1233, 134-144. doi: 10.1016/0005-2736(94)00235-H
92. Li, B., Xu, H., Li, Z., Yao, M., Xie, M., Shen, H., et al. (2012a). Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int. J. Nanomedicine 7, 187-197. doi: 10.2147/IJN.S27864
93. Li, F., and Sethi, G. (2010). Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805, 167-180. doi: 10.1016/j.bbcan.2010.01.002
94. Li, K., Chen, B., Xu, L., Feng, J., Xia, G., Cheng, J., et al. (2013a). Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in-vitro and in-vivo. Int. J. Nanomedicine 8, 1867-1877. doi: 10.2147/IJN.S43752
95. Li, M.-H., Choi, S., Thomas, T., Desai, A., Lee, K.-H., Holl, M., et al. (2012b). Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting. Eur. J. Med. Chem. 47, 560-572. doi: 10.1016/j.ejmech.2011.11.027
96. Li, P., Zhou, G., Zhu, X., Li, G., Yan, P., Shen, L., et al. (2012c). Photodynamic therapy with hyperbranched poly(ether-ester) chlorin(e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagnosis Photodyn. Ther. 9, 76-82. doi: 10.1016/j.pdpdt.2011.08.001
97. Li, X., Chen, Y., Wang, M., Ma, Y., Xia, W., and Gu, H. (2013b). A mesoporous silica nanoparticle - PEI - fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 34, 1391-1401. doi: 10.1016/j.biomaterials.2012.10.072
98. Li, X., Xie, Q., Zhang, J., Xia, W., and Gua, H. (2011). The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 32, 9546-9556. doi: 10.1016/j.biomaterials.2011.08.068
99. Ling, Y., Wei, K., Zou, F., and Zhong, S. (2012). Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int. J. Pharm. 430, 266-275. doi: 10.1016/j.ijpharm.2012.03.047
100. Liu, Q., Zhang, J., Xia, W., and Gu, H. (2012). Magnetic field enhanced cell uptake efficiency of magnetic silica mesoporous nanoparticles. Nanoscale 4, 3415-3421. doi: 10.1039/c2nr30352c
101. Liu, X., Ryland, L., Yang, J., Liao, A., Aliaga, C., Watts, R., et al. (2010). Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 116, 4192-4201. doi: 10.1182/blood-2010-02-271080
102. Liu, X., and Sun, J. (2010). Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways. Biomaterials 31, 8198-8209. doi: 10.1016/j.biomaterials.2010.07.069
103. Liu, Y., Lillehei, K., Cobb, W., Christians, U., and Ng, K. (2001). Overcoming MDR by ultrasound-induced hyperthermia and P-glycoprotein modulation. Biochem. Biophys. Res. Commun. 289, 62-68. doi: 10.1006/bbrc.2001.5938
104. Lu, F., Doane, T., Zhu, J., and Burda, C. (2012). Gold nanoparticles for diagnostic sensing and therapy. Inorg. Chim. Acta 393, 142-153. doi: 10.1016/j.ica.2012.05.038
105. Lu, H., Syu, W., Nishiyama, N., Kataoka, K., and Lai, P. (2011). Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in-vivo. J. Control. Release 155, 458-464. doi: 10.1016/j.jconrel.2011.06.005
106. Luk, B., Fang, R., and Zhang, L. (2012). Lipid and polymer-based nanostructures for cancer theranostics. Theranostics 2, 1117-1126. doi: 10.7150/thno.4381
107. Luo, C., Zhu, Y., Jiang, T., Lu, X., Zhang, W., Jing, Q., et al. (2007). Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology 229, 245-252. doi: 10.1016/j.tox.2006.10.020
108. Luqman, S., and Pezzuto, J. (2010). NF-κB: a promising target for natural products in cancer chemoprevention. Phytother. Res. 24, 949-963. doi: 10.1002/ptr.3171
109. Ma, P., Benhabbour, S., Feng, L., and Mumper, R. (2013). 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett. 334, 253-262. doi: 10.1016/j.canlet.2012.08.009
110. Ma, P., Dong, X., Swadley, C., Gupte, A., Leggas, M., Ledeburand, H., et al. (2009). Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome P-gp mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 5, 151-161. doi: 10.1166/jbn.2009.1021
111. MacDiarmid, J., Amaro-Mugridge, N., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., et al. (2009). Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27, 643-651. doi: 10.1038/nbt.1547
112. Maeng, J., Lee, D., Jung, K., Bae, Y., Park, I., Jeong, S., et al. (2010). Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 31, 4995-5006. doi: 10.1016/j.biomaterials.2010.02.068
113. Magné, N., Toillon, R., Bottero, V., Didelot, C., Van Houtte, P., Gérard, J., et al. (2006). NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 231, 158-168. doi: 10.1016/j.canlet.2005.01.022
114. Mai, W., and Meng, H. (2013). Mesoporous silica nanoparticles: a multifunctional nanotherapeutic system. Integr. Biol. (Camb.) 5, 19-28. doi: 10.1039/c2ib20137b
115. Majd, M., Asgari, D., Barar, J., Valizadeh, H., Kafil, V., Abadpour, A., et al. (2013). Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf. B Biointerfaces 106, 117-125. doi: 10.1016/j.colsurfb.2013.01.051
116. Mamaeva, V., Sahlgren, C., and Lindén, M. (2013). Mesoporous silica nanoparticles in medicine-recent advances. Adv. Drug Deliv. Rev. 65, 689-702. doi: 10.1016/j.addr.2012.07.018
117. Marin, A., Sun, H., Husseini, G., Pitt, W., Christensen, D., and Rapoport, N. (2002). Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake. J. Control. Release 84, 39-47. doi: 10.1016/S0168-3659(02)00262-6
118. Mei, L., Zhang, Y., Zheng, Y., Tian, G., Song, C., Yang, D., et al. (2009). A novel docetaxel-loaded poly (e-Caprolactone)/Pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res. Lett. 4, 1530-1539. doi: 10.1007/s11671-009-9431-6
119. Mendoza, A., Préat, V., Mollinedo, F., and Blanco-Prieto, M. (2011). In-vitro and in-vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156, 421-426. doi: 10.1016/j.jconrel.2011.07.030
120. Miao, J., Du, Y., Yuan, H., Zhang, X., and Hu, F. (2013). Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf. B Biointerfaces 110, 74-80. doi: 10.1016/j.colsurfb.2013.03.037
121. Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., and Gasco, M. (2000). Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210, 61-67. doi: 10.1016/S0378-5173(00)00562-7
122. Milane, L., Ganesh, S., Shah, S., Duan, Z., and Amiji, M. (2011). Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells and multifunctional nanotechnology. J. Control. Release 155, 237-247. doi: 10.1016/j.jconrel.2011.03.032
123. Min, K., Park, K., Kim, Y., Bae, S., Lee, S., Jo, H., et al. (2008). Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 127, 208-218. doi: 10.1016/j.jconrel.2008.01.013
124. Morad, S., Madigan, J., Levin, J., Abdelmageed, N., Karimi, R., Rosenberg, D., et al. (2013). Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem. Pharmacol. 85, 1057-1065. doi: 10.1016/j.bcp.2013.01.015
125. Na, J., Koo, H., Lee, S., Min, K., Park, K., Yoo, H., et al. (2011). Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials 32, 5252-5261. doi: 10.1016/j.biomaterials.2011.03.076
126. Nadali, F., Pourfathollah, A., and Alimoghaddam, C. (2007). Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology 12, 393-401. doi: 10.1080/10245330701283991
127. Nair, H., Anand, P., Sung, B., Kunnumakkara, A., Yadav, V., Tekmal, R., et al. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol. 79, 330-338. doi: 10.1016/j.bcp.2009.09.003
128. Némati, F., Dubernet, C., Fessi, H., Colin de Verdière, A., Poupon, M., Puisieux, F., et al. (1996). Reversion of multidrug resistance using nanoparticles in vitro: influence of the nature of the polymer. Int. J. Pharm. 138, 237-246. doi: 10.1016/0378-5173(96)04559-0
129. Newell, B., Wang, Y., and Irudayaraj, J. (2012). Multifunctional gold nanorod theragnostics probed by multi-photon imaging, Eur. J. Med. Chem. 48, 330-337. doi: 10.1016/j.ejmech.2011.12.036
130. Nieth, C., Priebsch, A., Stege, A., and Lage, H. (2003). Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545, 144-150. doi: 10.1016/S0014-5793(03)00523-4
131. Nishiyama, N., Nakagishi, Y., Morimoto, Y., Lai, P., Miyazaki, K., Urano, K., et al. (2009). Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine. J. Control. Release 133, 245-251. doi: 10.1016/j.jconrel.2008.10.010
132. Noguchi, S., Hirashima, N., Furuno, T., and Nakanishi, M. (2003). Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide. J. Control. Release 88, 313-320. doi: 10.1016/S0168-3659(02)00484-4
133. Nombona, N., Maduray, K., Antunes, E., Karsten, A., and Nyokong, T. (2012). Synthesis of phthalocyanine conjugates with gold nanoparticles and liposomes for photodynamic therapy. J. Photochem. Photobiol. B Biol. 107, 35-44. doi: 10.1016/j.jphotobiol.2011.11.007
134. O'Donnell, J., Joyce, M., Shannon, A., Harmey, J., Geraghty, J., and Bouchier-Hayes, D. (2006). Oncological implications of hypoxia inducible factor-1a (HIF-1a) expression. Cancer Treat. Rev. 32, 407-416. doi: 10.1016/j.ctrv.2006.05.003
135. Okayama, R., Noji, M., and Nakanishi, M. (1997). Cationic cholesterol with a hydroxyethylamino head group promotes significantly liposome-mediated gene transfection. FEBS Lett. 408, 232-234. doi: 10.1016/S0014-5793(97)00431-6
136. Otranto, M., Sarrazy, V., Bonte, F., Hinz, B., Gabbiani, G., and Desmouliere, A. (2012). The role of the myofibroblast in tumor stroma remodelling. Cell Adh. Migr. 6, 1-49. doi: 10.4161/cam.20377
137. Ozben, T. (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580, 2903-2909. doi: 10.1016/j.febslet.2006.02.020
138. Pan, L., Liu, J., He, Q., Wang, L., and Shi, J. (2013). Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 34, 2719-2730. doi: 10.1016/j.biomaterials.2012.12.040
139. Paszko, E., Vaz, G., Ehrhardt, C., and Senge, M. (2013). Transferrin conjugation does not increase the efficiency of liposomal Foscan during in vitro photodynamic therapy of oesophageal cancer. Eur. J. Pharm. Sci. 48, 202-210. doi: 10.1016/j.ejps.2012.10.018
140. Patil, Y., Sadhukh, T., Ma, L., and Panyam, T. (2009b). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136, 21-29. doi: 10.1016/j.jconrel.2009.01.021
141. Patil, Y., Swaminathan, S., Sadhukha, T., Ma, L., and Panyam, J. (2010). The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31, 358-365. doi: 10.1016/j.biomaterials.2009.09.048
142. Patil, Y., Toti, U., Khdair, A., Ma, L., and Panyam, J. (2009a). Single step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 30, 859-866. doi: 10.1016/j.biomaterials.2008.09.056
143. Pettus, B., Chalfant, C., and Hannun, Y. (2002). Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta 1585, 114-125. doi: 10.1016/S1388-1981(02)00331-1
144. Pramanik, D., Campbell, N., Das, S., Gupta, S., Chenna, V., Bisht, S., et al. (2012). A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 3, 640-650.
145. Prasad, P., Shuhendler, A., Cai, P., Rauth, A., and Wu, X. (2013). Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett. 334, 263-273. doi: 10.1016/j.canlet.2012.08.008
146. Rapisarda, A., and Melillo, G. (2009). Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Update 12, 74-80. doi: 10.1016/j.drup.2009.03.002
147. Rapoport, N. (2004). Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int. J. Pharm. 277, 155-162. doi: 10.1016/j.ijpharm.2003.09.048
148. Ren, Y., Wang, Y., Zhang, Y., and Wei, D. (2008). Overcoming multidrug resistance in human carcinoma cells by an antisense-oligodeoxynucleotide-doxorubicin conjugate in vitro and in vivo. Mol. Pharm. 5, 579-587. doi: 10.1021/mp800001j
149. Robey, R., Shukla, S., Finley, E., Oldham, R., Barnett, D., Ambudkar, S., et al. (2008). Inhibition of P-glycoprotein (ABCB1) - and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®. Biochem. Pharmacol. 75, 1302-1312. doi: 10.1016/j.bcp.2007.12.001
150. Rofstad, E. (2000). Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 76, 589-605. doi: 10.1080/095530000138259
151. Ronaldson, P., Ashraf, T., and Bendayan, R. (2010). Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol. Pharmacol. 77, 644-659. doi: 10.1124/mol.109.059410
152. Ryu, J., Kim, S., Koo, H., Yhee, J., Lee, A., Na, J., et al. (2011). Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis. J. Mater. Chem. 21, 17631-17634. doi: 10.1039/c1jm13064a
153. Saad, M., Garbuzenko, O., and Minko, T. (2008). Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 3, 761-776. doi: 10.2217/17435889.3.6.761
154. Sadeghi-Aliabadi, H., Mozaffari, M., Behdadfar, B., Raesizadeh, M., and Zarkesh-Esfahani, H. (2013). Preparation and cytotoxic evaluation of magnetite (Fe3O4) nanoparticles on breast cancer cells and its combinatory effects with doxorubicin used in hyperthermia. Avicenna J. Med. Biotechnol. 5, 96-103.
155. Sahay, G., Kim, J., and Kabanov, A. (2010). The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomat 31, 923-933. doi: 10.1016/j.biomaterials.2009.09.101
156. Santhosh, P., and Ulrih, N. (2013). Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics. Cancer Lett. 336, 8-17. doi: 10.1016/j.canlet.2013.04.032
157. Savla, R., Taratula, O., Garbuzenko, O., and Minko, T. (2011). Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control Rel. 153, 16-22. doi: 10.1016/j.jconrel.2011.02.015
158. Schleich, N., Sibret, P., Danhier, P., Ucakar, B., Laurent, S., Muller, R., et al. (2013). Dual anticancer drug/superparamagnetic iron oxide loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm. 447, 94-101. doi: 10.1016/j.ijpharm.2013.02.042
159. Schornack, P., and Gillies, R. (2003). Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia 5, 135-145. doi: 10.1016/S1476-5586(03)80005-2
160. Schreck, R., Meier, B., Männel, D., Dröge, W., and Baeuerle, P. (1992). Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175, 1181-1194. doi: 10.1084/jem.175.5.1181
161. Schwartz, S., Hernandez, A., and Evers, B. (1999). The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies. Surg. Oncol. 8, 143-153. doi: 10.1016/S0960-7404(00)00012-8
162. Sekhon, B. (2012). Current scenario on impact of nanomedicine. J. Pharm. Educ. Res. 3, 71-76.
163. Shabbits, J., and Mayer, L. (2003). Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim. Biophys. Acta. 1612, 98-106. doi: 10.1016/S0005-2736(03)00108-1
164. Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., et al. (2008). Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control Rel. 131, 220-227. doi: 10.1016/j.jconrel.2008.07.031
165. Sharom, F. (1997). The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160, 161-175. doi: 10.1007/s002329900305
166. Shen, J., He, Q., Gao, Y., Shi, J., and Li, Y. (2011). Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale 3, 4314-4322. doi: 10.1039/c1nr10580a
167. Shen, J., Yin, Q., Chen, L., Zhang, Z., and Li, Y. (2012). Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33, 8613-8624. doi: 10.1016/j.biomaterials.2012.08.007
168. Siddiqui, A., Patwardhan, G., Liu, Y., and Nazzal, S. (2010). Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int. J. Pharm. 400, 251-259. doi: 10.1016/j.ijpharm.2010.08.044
169. Siegal, T., Horowitz, A., and Gabizon, A. (1995). Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83, 1029-1037. doi: 10.3171/jns.1995.83.6.1029
170. Simon, S., Roy, D., and Schindler, M. (1994). Intracellular pH and the control of multi-drug resistance. Proc. Natl. Acad. Sci. U.S.A. 91, 1128-1132. doi: 10.1073/pnas.91.3.1128
171. Singh, A., Fahima, D., and Sahoo, S. (2011). Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS ONE 6:e26803. doi: 10.1371/journal.pone.0026803
172. Singh, S., and Kaur, H. (in press). Tumor microenvironment: a review. J. Oral Maxillofac. Surg. Med. Pathol. doi: 10.1016/j.ajoms.2012.12.011
173. Song, X., Cai, Z., Zheng, Y., He, G., Cui, F., Gong, D., et al. (2009). Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 37, 300-305. doi: 10.1016/j.ejps.2009.02.018
174. Stover, T., Kim, Y., Lowe, T., and Kester, M. (2008). Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29, 359-369. doi: 10.1016/j.biomaterials.2007.09.037
175. Susa, M., Iyer, A., Ryu, K., Choy, E., Hornicek, F., Mankin, H., et al. (2010). Inhibition of ABCB1 (MDR1) expression by a siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS ONE 5:10764. doi: 10.1371/journal.pone.0010764
176. Tang, M., Lei, L., Guo, S., and Huang, W. (2010). Recent progress in nanotechnology for cancer therapy. Chin. J. Cancer 29, 775-780. doi: 10.5732/cjc.010.10075
177. Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O., and Minko, T. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 171, 349-357. doi: 10.1016/j.jconrel.2013.04.018
178. Tas, S., Vervoordeldonk, M., and Tak, P. (2009). Gene therapy targeting nuclear factor-κB: towards clinical application in inflammatory diseases and cancer. Curr. Gene Ther. 9, 160-170. doi: 10.2174/156652309788488569
179. Teng, I., Chang, Y., Wang, L., Lu, H., Wu, L., Yang, C., et al. (2013). Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials 34, 7462-7470. doi: 10.1016/j.biomaterials.2013.06.001
180. Teow, H., Zhou, Z., Najlah, M., Yusof, S., Abbott, N., and D'Emanuele, A. (2013). Delivery of Paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int. J. Pharm. 441, 701-711. doi: 10.1016/j.ijpharm.2012.10.024
181. Thakor, A., Jokerst, J., Zavaleta, C., Massoud, T., and Gambhir, S. (2011). Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett. 11, 4029-4036. doi: 10.1021/nl202559p
182. Thomas, C., Ferris, D., Lee, J., Choi, E., Cho, M., Kim, E., et al. (2010). Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J. Am. Chem. Soc. 132, 10623-10625. doi: 10.1021/ja1022267
183. Thomas, H., and Coley, H. (2003). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165.
184. Tomida, A., and Tsuruo, T. (2002). "Drug resistance pathways as targets," in Anticancer Drug Development, Chapter 5, eds B. C. Baguley and D. J. Kerr (Tokyo: Academic Press), 77-90.
185. van Kempen, L., Ruiter, D., van Muijen, G., and Coussens, L. (2003). The tumor microenvironment: a critical determinant of neoplastic evolution. Eur. J. Cell Biol. 82, 539-548. doi: 10.1078/0171-9335-00346
186. van Vlerken, L., Duan, Z., Little, S., Seiden, M., and Amiji, M. (2008). Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol. Pharm. 5, 516-526. doi: 10.1021/mp800030k
187. van Vlerken, L., Duan, Z., Little, S., Seiden, M., and Amiji, M. (2010). Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J. 12, 171-180. doi: 10.1208/s12248-010-9174-4
188. Vekariya, K., Kaur, J., and Tikoo, K. (2012). ERa signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer. Nanomedicine 8, 1125-1132. doi: 10.1016/j.nano.2011.12.003
189. Velingkar, V., and Dandekar, V. (2010). Modulation of P-glycoprotein mediated multidrug resistance (MDR) in cancer using chemosensitizers. Int. J. Pharm. Sci. Res. 1, 104-111.
190. Venishetty, V., Komuravelli, R., Kuncha, M., Sistla, R., and Diwan, P. (2013). Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomed. Nanotechnol. Biol. Med. 9, 111-121. doi: 10.1016/j.nano.2012.03.003
191. Vigderman, L., and Zubarev, E. (2012). Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv. Drug Deliv. Rev. 65, 663-676. doi: 10.1016/j.addr.2012.05.004
192. Wan, C., Jackson, J., Pirmoradi, F., Chiao, M., and Burt, H. (2012). Increased accumulation and retention of micellar Paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. Ultrasound Med. Bio. 38, 736-744. doi: 10.1016/j.ultrasmedbio.2012.01.023
193. Wang, F., Zhang, D., Zhang, Q., Chen, Y., Zheng, D., Hao, L., et al. (2011a). Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 32, 9444-9456. doi: 10.1016/j.biomaterials.2011.08.041
194. Wang, H., Zheng, L., Peng, C., Guo, R., Shen, M., Shi, X., et al. (2011b). Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles. Biomaterials 32, 2979-2988. doi: 10.1016/j.biomaterials.2011.01.001
195. Wang, J., Tao, X., Zhang, Y., Wei, D., and Ren, Y. (2010). Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials 31, 4426-4433. doi: 10.1016/j.biomaterials.2010.02.007
196. Wang, L., Zeng, R., Li, C., and Qiao, R. (2009). Self-assembled polypeptide block poly (vinylpyrrolidone) as prospective drug delivery systems. Colloid Surf. B Biointerfaces 74, 284-292. doi: 10.1016/j.colsurfb.2009.07.032
197. Wang, X., Zhang, R., Wu, C., Dai, Y., Song, M., Gutmann, S., et al. (2007). The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J. Biomed. Mater. Res. A 80, 852-860. doi: 10.1002/jbm.a.30901
198. Weber, C., and Kuo, P. (2012). The tumor microenvironment. Surg. Oncol. 21, 172-177. doi: 10.1016/j.suronc.2011.09.001
199. Wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Shaa, X., et al. (2009). Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int. J. Pharm. 376, 176-185. doi: 10.1016/j.ijpharm.2009.04.030
200. Wei, Z., Yuan, S., Chen, Y., Yu, S., Hao, J., Luo, J., et al. (2010). Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 75, 341-353. doi: 10.1016/j.ejpb.2010.04.017
201. Wong, H., Bendayan, R., Rauth, A., and Wu, X. (2006). Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 116, 275-284. doi: 10.1016/j.jconrel.2006.09.007
202. Wouters, B., Koritzinsky, M., Chiu, R., and Theys, J. (2003). Modulation of cell death in the tumor microenvironment. Semin. Radiat. Oncol. 13, 31-41. doi: 10.1053/srao.2003.50004
203. Wu, C., Calcagno, A., and Ambudkar, S. (2008). Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 1, 93-105. doi: 10.2174/1874467210801020093
204. Wu, F., Shao, Z., Zhai, B., Zhao, C., and Shen, D. (2011). Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein. Ultrasound Med. Biol. 37, 151-159. doi: 10.1016/j.ultrasmedbio.2010.10.009
205. Wu, J., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X., et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharmacol. Pharm. Sci. 10, 350-357.
206. Xiao, J., Duan, X., Yin, Q., Miao, Z., Yu, H., Chen, C., et al. (2013). The inhibition of metastasis and growth of breast cancer by blocking the NF-κB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials 34, 5381-5390. doi: 10.1016/j.biomaterials.2013.03.084
207. Xie, J., Lee, S., and Chen, X. (2010). Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 62, 1064-1079. doi: 10.1016/j.addr.2010.07.009
208. Xu, Z., Chen, L., Gu, W., Gao, Y., Lin, L., Zhang, Z., et al. (2009). The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30, 226-232. doi: 10.1016/j.biomaterials.2008.09.014
209. Yabbarov, N., Posypanova, G., Vorontsov, E., Obydenny, S., and Severin, E. (2013). A new system for targeted delivery of doxorubicin into tumor cells. J. Control. Release 168, 135-141. doi: 10.1016/j.jconrel.2013.03.007
210. Yanan, W., Baoan, C., Jian, C., Feng, G., Wenlin, X., Jiahua, D., et al. (2009). Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerisating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int. J. Nanomedicine 4, 73-78.
211. Yang, W., Cheng, Y., Xu, T., Wang, X., and Wen, L. (2009a). Targeting cancer cells with biotin-dendrimer conjugates. Eur. J. Med. Chem. 44, 862-868. doi: 10.1016/j.ejmech.2008.04.021
212. Yang, X., Koh, C., Liu, S., Pan, X., Santhanam, R., Yu, B., et al. (2009b). Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol. Pharm. 6, 221-230. doi: 10.1021/mp800149s
213. Yared, J., and Tkaczuk, K. (2012). Update on taxane development: new analogs and new formulations. Drug Des. Devel. Ther. 6, 371-384.
214. Yoo, M., Park, I., Lim, H., Lee, S., Jiang, H., Kim, Y., et al. (2012). Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta Biomater. 8, 3005-3013. doi: 10.1016/j.actbio.2012.04.029
215. Yu, D., Wu, F., Liu, Y., Liu, H., and Xia, Q. (2013). Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. Biomed. Pharmacother. 67, 615-617. doi: 10.1016/j.biopha.2013.03.007
216. Zhang, G., Shi, L., Selke, M., and Wang, X. (2011a). CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation. Nanoscale Res. Lett. 6, 418. doi: 10.1186/1556-276X-6-418
217. Zhang, H., Yee, D., and Wang, C. (2008a). Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond.) 3, 83-91. doi: 10.2217/17435889.3.1.83
218. Zhang, P., Ling, G., Pan, X., Sun, J., Zhang, T., Pu, X., et al. (2012). Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomed. Nanotech. Biol. Med. 8, 185-193. doi: 10.1016/j.nano.2011.06.007
219. Zhang, P., Ling, G., Sun, J., Zhang, T., Yuan, Y., Sun, Y., et al. (2011b). Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. Biomaterials 32, 5524-5533. doi: 10.1016/j.biomaterials.2011.04.022
220. Zhang, T., Chen, J., Zhang, Y., Shen, Q., and Pan, W. (2011c). Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci. 43, 174-179. doi: 10.1016/j.ejps.2011.04.005
221. Zhang, X., Miao, J., Dai, Y., Du, Y., Yuan, H., and Hu, F. (2008b). Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm. 361, 239-244. doi: 10.1016/j.ijpharm.2008.06.002
222. Zhang, X., Xu, X., Lam, R., Giljohann, D., Ho, D., and Mirkin, C. (2011d). Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA nanoparticle conjugates. ACS Nano 5, 6962-6970. doi: 10.1021/nn201446c
223. Zhao, P., Wang, H., Gao, H., Li, C., and Zhang, Y. (2013). Reversal of multidrug resistance by magnetic chitosan-Fe3O4 nanoparticle-encapsulated MDR1 siRNA in glioblastoma cell line. Neurol. Res. 35, 821-828. doi: 10.1179/1743132813Y.0000000218
224. Zhou, R., Mazurchuk, R., and Straubinger, R. (2002). Antivasculature effects of doxorubicin containing liposomes in an intracranial rat brain tumor model. Cancer Res. 62, 2561-2566.
225. Zhou, Y., Shi, L., Li, Q., Jiang, H., Lv, G., Zhao, J., et al. (2010). Imaging and inhibition of multi-drug resistance in cancer cells via specific association with negatively charged CdTe quantum dots. Biomaterials 31, 4958-4963. doi: 10.1016/j.biomaterials.2010.02.053
226. Zingarelli, B., Sheehan, M., and Wong, H. (2003). Nuclear factor-[kappa] B as a therapeutic target in critical care medicine. Crit. Care Med. 31, S105-S111. doi: 10.1097/00003246-200301001-00015